The 5, 10 methylenetetrahydrofolate reductase (MTHFR) enzyme is a catalyst in the folate metabolism pathway, the byproducts of which are involved in the remethylation of homocysteine to methionine. Methionine is a precursor for a major DNA methyl donor and is important for DNA methylation and gene regulation. Rare mutations in the MTHFR gene have been associated with autosomal recessive MTHFR deficiency leading to homocystinuria. In addition, two polymorphic variants in this gene (C677T and A1298C) have been implicated in a mild form of MTHFR deficiency associated with hyperhomocysteinemia. Mild to moderate hyperhomocysteinemia has been previously implicated as a risk factor for cardiovascular disease. Further, the presence of these variants, with and without mildly elevated levels of homocysteine, has been studied in relation to several multifactorial disorders including recurrent pregnancy loss, neural tube defects and congenital anomalies, cancer, and neurodevelopmental disorders. Given this wide spectrum of purported clinical implications and the prevalence of these polymorphisms, genetic counselors may encounter questions regarding the significance of MTHFR polymorphisms in a variety of settings. Here we present a brief background of the MTHFR polymorphisms, review of the literature regarding clinical considerations, and discussion of relevant genetic counseling aspects through case vignettes. Educational resources for patients and providers are also included.
This is a preview of subscription content, access via your institution.
Aetna Clinical Policy Bulletin (25 June 2014). Homocysteine Testing. Retrieved from http://www.aetna.com/cpb/medical/data/700_799/0763.html. Accessed 24 Aug 2015.
Albert, C. M., Cook, N. R., Gaziano, J. M., Zaharris, E., MacFadyen, J., Danielson, E., et al. (2008). Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: A randomized trial. Journal of the American Medical Association, 299(17), 2027–2036.
American Academy of Family Physicians (2012). Summary of recommendations for clinical preventive services. Leawood (KS): American Academy of Family Physicians (AAFP).
American Academy of Pediatrics, Committee on Genetics (1999). Folic acid for the prevention of neural tube defects. Pediatrics, 104(2), 325–327.
American Congress of Obstetricians and Gynecologists (2013). Inherited thrombophilias in pregnancy. Washington (DC): American College of Obstetricians and Gynecologists (ACOG).
Bailey, L. B. (2003). Folate, methyl-related nutrients, alcohol, and the MTHFR 677C–>T polymorphism affect cancer risk: Intake recommendations. The Journal of Nutrition, 133(11 Suppl 1), 3748S–3753S.
Bellamy, J. (11 June 2015). Dubious MTHFR genetic mutation testing. Science Based Medicine. Retrieved from https://www.sciencebasedmedicine.org/dubious-mthfr-genetic-mutation-testing/.
Bezemer, I. D., Doggen, C. J., Vos, H. L., & Rosendaal, F. R. (2007). No association between the common MTHFR 677C→ T polymorphism and venous thrombosis: Results from the MEGA study. Archives of Internal Medicine, 167(5), 497–501.
Boccia, S., Hung, R., Ricciardi, G., Gianfagna, F., Ebert, M. P., Fang, J. Y., et al. (2008). Meta- and pooled analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer risk: A huge-GSEC review. American Journal of Epidemiology, 167(5), 505–516.
Botto, L. D., & Yang, Q. (2000). 5,10-methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review. American Journal of Epidemiology, 151(9), 862–877.
Cao, Y., Xu, J., Zhang, Z., Huang, X., Zhang, A., Wang, J., et al. (2013). Association study between methylenetetrahydrofolate reductase polymorphisms and unexplained recurrent pregnancy loss: A meta-analysis. Gene, 514(2), 105–111.
Cattaneo, M. (2006). Hyperhomocysteinemia and venous thromboembolism. Seminars in Thrombosis and Hemostasis, 32(7), 716–723.
Centers for Disease Control (CDC) (1991). Use of folic acid for prevention of spina bifida and other neural tube defects–1983-1991. MMWR. Morbidity and Mortality Weekly Report, 40(30), 513–516.
Clarke, R., Daly, L., Robinson, K., Naughten, E., Cahalane, S., Fowler, B., & Graham, I. (1991). Hyperhomocysteinemia: An independent risk factor for vascular disease. New England Journal of Medicine, 324(17), 1149–1155.
Clarke, R., Halsey, J., Lewington, S., Lonn, E., Armitage, J., Manson, J. E., et al. (2010). Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Archives of Internal Medicine, 170(18), 1622–1631.
Clarke, R., Bennett, D. A., Parish, S., Verhoef, P., Dötsch-Klerk, M., Lathrop, M., et al. (2012). Homocysteine and coronary heart disease: Meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Medicine, 9(2), 205.
Colson, N. J., Naug, H. L., Nikbakht, E., Zhang, P., & McCormack, J. (2015). The impact of MTHFR 677 C/T genotypes on folate status markers: a meta-analysis of folic acid intervention studies. European Journal of Nutrition, 1-14. Advanced online publication. doi:10.1007/s00394-015-1076-x.
Cordero, A. M., Crider, K. S., Rogers, L. M., Cannon, M. J., & Berry, R. J. (2015). Optimal serum and red blood cell folate concentrations in women of reproductive age for prevention of neural tube defects: World Health Organization guidelines. MMWR. Morbidity and Mortality Weekly Report, 64(15), 421–423.
Den Heijer, M., Lewington, S., & Clarke, R. (2005). Homocysteine, MTHFR and risk of venous thrombosis: A meta-analysis of published epidemiological studies. Journal of Thrombosis and Haemostasis, 3(2), 292–299.
Den Heijer, M., Willems, H. P., Blom, H. J., Gerrits, W. B., Cattaneo, M., Eichinger, S., et al. (2007). Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood, 109(1), 139–144.
Eldibany, M. M., & Caprini, J. A. (2007). Hyperhomocysteinemia and thrombosis: An overview. Archives of Pathology & Laboratory Medicine, 131(6), 872.
Finnell, R. H., Shaw, G. M., Lammer, E. J., & Volcik, K. A. (2002). Does prenatal screening for 5, 10-methylenetetrahydrofolate reductase (MTHFR) mutations in high-risk neural tube defect pregnancies make sense? Genetic Testing, 6(1), 47–52.
Friso, S., Choi, S. W., Girelli, D., Mason, J. B., Dolnikowski, G. G., Bagley, P. J., et al. (2002). A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proceedings of the National Academy of Sciences of the United States of America, 99(8), 5606–5611.
Frosst, P., Blom, H. J., Milos, R., Goyette, P., Sheppard, C. A., Matthews, R. G., et al. (1995). A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nature Genetics, 10(1), 111–113.
Gaysina, D., Cohen, S., Craddock, N., Farmer, A., Hoda, F., Korszun, A., et al. (2008). No association with the 5, 10-methylenetetrahydrofolate reductase gene and major depressive disorder: Results of the depression case control (DeCC) study and a meta-analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147(6), 699–706.
Gilbody, S., Lewis, S., & Lightfoot, T. (2007). Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A HuGE review. American Journal of Epidemiology, 165(1), 1–13.
Gouveia, L. O., & Canhão, P. (2010). MTHFR and the risk for cerebral venous thrombosis-a meta-analysis. Thrombosis Research, 125(4), 153–158.
Goyette, P., Frosst, P., Rosenblatt, D. S., & Rozen, R. (1995). Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. American Journal of Human Genetics, 56(5), 1052–1059.
Green, R. (2011). Indicators for assessing folate and vitamin B-12 status and for monitoring the efficacy of intervention strategies. The American Journal of Clinical Nutrition, 94(2), 666S–672S.
Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., et al. (2010). ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association. Journal of the American College of Cardiology, 56(25), 50–103.
Hainsworth, A. H., Yeo, N. E., Weekman, E. M., & Wilcock, D. M. (2015). Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID). Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. Advance online publication. doi:10.1016/j.bbadis.2015.11.015.
Helfand, M., Buckley, D. I., Freeman, M., Fu, R., Rogers, K., Fleming, C., & Humphrey, L. L. (2009). Emerging risk factors for coronary heart disease: A summary of systematic reviews conducted for the US preventive services task force. Annals of Internal Medicine, 151(7), 496–507.
Hickey, S. E., Curry, C. J., & Toriello, H. V. (2013). American College of Medical Genetics Practice guideline: Lack of evidence for MTHFR polymorphism testing. Genetics in Medicine, 15(2), 153–156.
Homocysteine Studies Collaboration (2002). Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. Journal of the American Medical Association, 288(16), 2015–2022.
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin, KA (April 2015) (eds). SEER Cancer Statistics Review, 19752012, National cancer institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site.
Hu, C., Qian, Z., Gong, F., Lu, S., Feng, F., Wu, Y., et al. (2014). Methylenetetrahydrofolate reductase (MTHFR) polymorphism susceptibility to schizophrenia and bipolar disorder: An updated meta-analysis. Journal of Neural Transmission, 122(2), 307–320.
Huang, T., Chen, Y., Yang, B., Yang, J., Wahlqvist, M. L., & Li, D. (2012). Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality. Clinical Nutrition, 31(4), 448–454.
Hubner, R. A., & Houlston, R. S. (2007). MTHFR C677T and colorectal cancer risk: A meta-analysis of 25 populations. International Journal of Cancer, 120(5), 1027–1035.
Huemer, M., Mulder-Bleile, R., Burda, P., Froese, D. S., Suormala, T., Zeev, B., et al. (2015). Clinical pattern, mutations and in vitro residual activity in 33 patients with severe 5, 10 methylenetetrahydrofolate reductase (MTHFR) deficiency. Journal of Inherited Metabolic Disease, 1–10.
Johnson, C. (11 September 2015). Why you shouldn’t know too much about your own genes. The Washington Post. Retrieved from https://www.washingtonpost.com/news/wonk/wp/2015/09/11/the-powerful-argument-for-not-learning-too-much-about-your-genes/.
Kang, S. S., Wong, P. W., Susmano, A., Sora, J., Norusis, M., & Ruggie, N. (1991). Thermolabile methylenetetrahydrofolate reductase: An inherited risk factor for coronary artery disease. American Journal of Human Genetics, 48(3), 536–545.
Keijzer, M. B., Borm, G. F., Blom, H. J., Bos, G. M., Rosendaal, F. R., & den Heijer, M. (2007). No interaction between factor V leiden and hyperhomocysteinemia or MTHFR 677TT genotype in venous thrombosis-results of a meta-analysis of published studies and a large case-only study. Thrombosis and Haemostasis, 97(1), 32–37.
Klerk, M., Verhoef, P., Clarke, R., Blom, H. J., Kok, F. J., & Schouten, E. G. (2002). MTHFR 677C→ T polymorphism and risk of coronary heart disease: A meta-analysis. Journal of the American Medical Association, 288(16), 2023–2031.
Laurino, M. Y., Bennett, R. L., Saraiya, D. S., Baumeister, L., Doyle, D. L., Leppig, K., et al. (2005). Genetic evaluation and counseling of couples with recurrent miscarriage: Recommendations of the national society of genetic counselors. Journal of Genetic Counseling, 14(3), 165–181.
Ledowsky, C. (2015). Folic Acid and 5-MTHF in Treating MTHFR Deficiency. MTHFR Support Australia. Retrieved from http://www.mthfrsupport.com.au/folic-acid-vs-5-mthf-treating-mthfr-deficiency/.
Lynch, B. (2016). MTHFR.Net: your expert resource on MTHFR Gene Mutations. Retrieved from http://www.mthfr.net.
Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G. (2009) Homocysteine lowering interventions for preventing cardiovascular events.Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD006612. (Updated Version 4: Martí-Carvajal AJ, Solà I, Lathyris D. (2015) Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No.: CD006612. doi:10.1002/14651858.CD006612.pub4.).
Moll, S., & Varga, E. A. (2015). Homocysteine and MTHFR mutations. Circulation, 132(1), 6–9.
Molloy, A. M., Mills, J. L., Kirke, P. N., Ramsbottom, D., McPartlin, J. M., Burke, H., et al. (1998). Low blood folates in NTD pregnancies are only partly explained by thermolabile 5,10-methylenetetrahydrofolate reductase: Low folate status alone may be the critical factor. American Journal of Medical Genetics, 78(2), 155–159.
Morris, M. S., Jacques, P. F., Rosenberg, I. H., & Selhub, J. (2007). Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. The American Journal of Clinical Nutrition, 85(1), 193–200.
MRC Vitamin Study Research Group (1991). Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. The Lancet, 338(8760), 131–137.
Mudd, S. H., Uhlendorf, B. W., Freeman, J. M., Finkelstein, J. D., & Shih, V. E. (1972). Homocystinuria associated with decreased methylenetetrahydrofolate reductase activity. Biochemical and Biophysical Research Communications, 46(2), 905–912.
Nagele, P., Meissner, K., Francis, A., Fodinger, M., & Saccone, N. L. (2011). Genetic and environmental determinants of plasma total homocysteine levels: Impact of population-wide folate fortification. Pharmacogenetics and Genomics, 21(7), 426–431.
Picker JD, Levy HL. (2014). Homocystinuria caused by cystathionine beta-synthase deficiency. 2004 Jan 15 [Updated 2014 Nov 13]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle.
Pu, D., Shen, Y., & Wu, J. (2013). Association between MTHFR gene polymorphisms and the risk of autism spectrum disorders: A Meta-Analysis. Autism Research, 6(5), 384–392.
Qi, X., Ma, X., Yang, X., Fan, L., Zhang, Y., Zhang, F., et a. (2010). Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: A meta-analysis from 41 studies with 16,480 cases and 22,388 controls. Breast Cancer Research and Treatment, 123(2), 499–506.
Ray, J. G., Kearon, C., Yi, Q., Sheridan, P., & Lonn, E. (2007). Homocysteine-lowering therapy and risk for venous thromboembolism: A randomized trial. Annals of Internal Medicine, 146(11), 761–767.
Ren, A., & Wang, J. (2006). Methylenetetrahydrofolate reductase C677T polymorphism and the risk of unexplained recurrent pregnancy loss: A meta-analysis. Fertility and Sterility, 86(6), 1716–1722.
Rey, E., Kahn, S. R., David, M., & Shrier, I. (2003). Thrombophilic disorders and fetal loss: A meta-analysis. The Lancet, 361(9361), 901–908.
Rozen, R. (1996). Molecular genetics of methylenetetrahydrofolate reductase deficiency. Journal of Inherited Metabolic Disease, 19(5), 589–594.
Sharp, L., & Little, J. (2004). Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: A HuGE review. American Journal of Epidemiology, 159(5), 423–443.
Skeptical Raptor's Blog (7 May 2015). MTHFR gene mutations are the root of all health problems. Skeptical Raptor's Blog: GENETICS, Nutrition, Vaccines. Retrieved from http://www.skepticalraptor.com/skepticalraptorblog.php/mthfr-gene-mutations-are-the-root-of-all-health-problems/.
Teng, Z., Wang, L., Cai, S., Yu, P., Wang, J., Gong, J., & Liu, Y. (2013). The 677C>T (rs1801133) polymorphism in the MTHFR gene contributes to colorectal cancer risk: A meta-analysis based on 71 research studies. PloS One, 8(2), e55332.
Thrombosis Canada, (19 January 2015). Thrombophilia: Homocystinemia and Methylene Tetrahydrofolate Reductase. Available at http://thrombosiscanada.ca/?page_id=18#.
Troen, A. M., Mitchell, B., Sorensen, B., Wener, M. H., Johnston, A., Wood, B., et al. (2006). Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. The Journal of Nutrition, 136(1), 189–194.
Tsai, M. Y., Loria, C. M., Cao, J., Kim, Y., Siscovick, D., Schreiner, P. J., et al. (2009). Clinical utility of genotyping the 677C>T variant of methylenetetrahydrofolate reductase in humans is decreased in the post-folic acid fortification era. The Journal of Nutrition, 139(1), 33–37.
Tsang, B. L., Devine, O. J., Cordero, A. M., Marchetta, C. M., Mulinare, J., Mersereau, P., et al. (2015). Assessing the association between the methylenetetrahydrofolate reductase (MTHFR) 677C> T polymorphism and blood folate concentrations: a systematic review and meta-analysis of trials and observational studies. The American Journal of Clinical Nutrition, 101(6), 1286–1294.
UpToDate (2012). Overview of Homocysteine. Waltham, MA: UpToDate 2012. Available at http://www.uptodate.com/contents/overview-of-homocysteine?source=machineLearning&search=homocysteine&selectedTitle=1%7E146§ionRank=1&anchor=H2#H2. Accessed 24 Sept 2013.
Wang, H., Wang, J., Zhao, L., Liu, X., & Mi, W. (2012a). Methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia-evidence from an updated meta-analysis including 35 studies. BMC Medical Genetics, 13, 77.
Wang, X. W., Luo, Y. L., Wei Wang, M., Zhang, Y., Chen, Q., & Cheng, Y. L. (2012b). Association between MTHFR A1298C polymorphism and neural tube defect susceptibility: A meta-analysis. Obstetrics and Gynecology, 206(251), 1–7.
Williams, J., Mai, C. T., Mulinare, J., Isenburg, J., Flood, T. J., Ethen, M., et al. (2015). Updated estimates of neural tube defects prevented by mandatory folic acid fortification-United States, 1995–2011. MMWR Morbidity and Mortality Weekly Report, 64(1), 1–5.
Yang, Q. H., Botto, L. D., Gallagher, M., Friedman, J. M., Sanders, C. L., Koontz, D., et al. (2008). Prevalence and effects of gene-gene and gene-nutrient interactions on serum folate and serum total homocysteine concentrations in the United States: Findings from the third national health and nutrition examination survey DNA Bank. The American Journal of Clinical Nutrition, 88(1), 232–246.
Yang, Y., Chen, J., Wang, B., Ding, C., & Liu, H. (2015). Association between MTHFR C677T polymorphism and neural tube defect risks: A comprehensive evaluation in three groups of NTD patients, mothers, and fathers. Birth Defects Research. Part A, Clinical and Molecular Teratology, 103(6), 488–500.
Zappacosta, B., Mastroiacovo, P., Persichilli, S., Pounis, G., Ruggeri, S., Minucci, A., et al. (2013). Homocysteine lowering by folate-rich diet or pharmacological supplementations in subjects with moderate hyperhomocysteinemia. Nutrients, 5(5), 1531–1543.
Zhang, T., Lou, J., Zhong, R., Wu, J., Zou, L., Sun, Y., et al. (2013). Genetic variants in the folate pathway and the risk of neural tube defects: a meta-analysis of the published literature. PloS One, 8(4), e59570.
Zintzaras, E. (2006). Methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: A meta-analysis. Clinical Genetics, 69(4), 327–336.
The authors would like to thank Amy Dunn, MD, Scott Hickey, MD, Sarah O’Brien, MD, and Kristin Zajo, MS, LGC for careful review of this manuscript.
Conflicts of Interest
Brooke Levenseller Levin and Elizabeth Varga declare that they have no conflict of interest.
About this article
Cite this article
Levin, B.L., Varga, E. MTHFR: Addressing Genetic Counseling Dilemmas Using Evidence-Based Literature. J Genet Counsel 25, 901–911 (2016). https://doi.org/10.1007/s10897-016-9956-7
- Methylenetetrahydrofolate reductase (MTHFR)
- Genetic counseling